azd9150
Small moleculeexperimental
Clinical trial activity
9 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2013 (NCT01839604)
Timeline
Indications
Studied for
- Ascites · Phase 2
- Carcinoma, Hepatocellular · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Colorectal Neoplasms · Phase 2
- DNA Mismatch Repair · Phase 2
- Gastrointestinal Neoplasms · Phase 2
- Lung Neoplasms · Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Lymphoma, Large-Cell, Immunoblastic · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1/Phase 2
Mechanism of action
STAT3 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- azd9150
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03527147 | Phase 1 | Jun 30, 2018 | Acerta Pharma, AstraZeneca, Tennessee Oncology, PLLC |
| NCT03421353 | Phase 1/Phase 2 (Phase 2) | Feb 7, 2018 | AstraZeneca, Tennessee Oncology, PLLC |
| NCT03394144 | Phase 1 | Jan 30, 2018 | AstraZeneca |
| NCT03334617 | Phase 2 | Dec 18, 2017 | AstraZeneca, University of Texas at Houston |
| NCT02983578 | Phase 2 | Mar 2, 2017 | AstraZeneca, University of Texas at Houston |
| NCT02549651 | Phase 1 | Jul 19, 2016 | MedImmune |
| NCT02499328 | Phase 1/Phase 2 (Phase 2) | Aug 5, 2015 | AstraZeneca, MedImmune, University of Texas at Houston |
| NCT02417753 | Phase 2 | Apr 3, 2015 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT01839604 | Phase 1 | May 1, 2013 | AstraZeneca, Ionis Pharmaceuticals, Inc. |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 7 | 5 | 2 | 2013 |
| University of Texas at Houston | Academic/Hospital | 3 | 1 | 1 | 2015 |
| MedImmune | For profit | 2 | 1 | 2 | 2015 |
| Tennessee Oncology, PLLC | Academic/Hospital | 2 | 0 | 2 | 2018 |
| Acerta Pharma | For profit | 1 | 1 | 1 | 2018 |
| Ionis Pharmaceuticals, Inc. | For profit | 1 | 0 | 1 | 2013 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2015 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2015 |
8 organizations
Page 1 / 1